Press releases

An existing licensing agreement with Angiotech Pharmaceuticals, Inc. allows Company to obtain an exclusive license for the use of paclitaxel and other agents in the coronary vascular field.

French government adds new patient categories to reimbursement approval criteria.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Equity investment in a privately held company developing a balloon-expandable, bioresorbable drug-eluting stent.

The two series of senior notes will have varied maturities and a combined aggregate principal amount of $500 million.